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Rutin is available in some foods, fruits, and vegetables. It has various beneficial medical effects making it useful in the treatment of
various diseases. Rutin is available in different oral dosage forms such as tablets or capsules, widely available in themarket. Rutin and
many herbal medicines lack quality control due to unavailability of analytical methods. In this study, we formulated rutin tablet and
studied its stability using a simple developed analytical method.The dissolution profile of our formulated tablet was also inspected.
The results showed that our developed method was linear (𝑅2 = 0.999), precise (% RSD = 0.026), and accurate (% recovery =
98.55–103.34). The formulated rutin tablet was stable under accelerated conditions as well as room temperature for 150 days (%
assay > 91.69). The dissolution profile over 45 minutes of our formulated tablet showed a better dissolution (26.5%) compared
with the internationally marketed Rutin tablet (18.5%). This study can serve as a guideline to companies that manufacture herbal
products to improve their formulated herbs and apply validated analytical methods to check the quality of their product.
1. Introduction
Rutin is 3,3󸀠,4󸀠,5,7-pentahydroxy flavones-3-rutinoside. It
is the yellow crystalline rhamnoglucoside of the flavonoid
quercetin and has a chemical formula C
27
H
30
O
16
with chem-
ical structure as shown in Figure 1.
Rutin is slightly soluble in water and has a higher
solubility in organic solvent such as methanol. It showed
low bioavailability after studying it in animals and human
volunteers, due to its low water solubility [1].
Rutin is found in some foods, fruits, vegetables, and plant-
based beverages such as buckwheat, onions, apples, berries,
orange, grape fruit, lemon, tea, and asparagus. Rutin has
various beneficialmedical effects: it possesses antioxidant and
anti-inflammatory effects and is widely used for hemorrhage
and varicose [2, 3].
Various dosage forms are available in the local and
international market such as tablets and capsules and in
topical applications such as gels. Rutin is available in these
dosage forms either alone or in combination with other
active ingredients. Liquid chromatography and UV spec-
trophotometer methods are the most popular methods of
rutin analysis [4, 5]. Tablets are the mostly used dosage
forms available in themarket. Formulations of tablets include
diluents, binders, and disintegrants. The selection of these
excipients should take into consideration the physical and
chemical properties which include compatibility, flowability,
solubility, hygroscopicity, lubricity, and its effect on stability
of the tablet [6–10].
Employment of a fully validated analytical method is
highly needed to quantify rutin in various dosages. The typi-
cal validation parameters should be considered in the analyt-
ical validation procedure; these parameters include accuracy,
precision, repeatability, intermediate precision, specificity,
detection limit, quantitation limit, linearity, and range [11–
15]. The ICH guidelines clearly stated the requirement and
establishment of stability-indicating assaymethod. It requires
the conduct of forced decomposition studies under a variety
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Figure 1: Chemical structure of rutin.
of conditions, like pH, light, oxidation, and dry heat.Thedrug
must be separated from the degradation products and the
method must be able to analyze each individual degradation
product [16, 17].
To our knowledge, there is no pharmacopeial method or
any validated method that quantifies rutin in its final dosage
form.The objective of this study is to formulate a rutin tablet
and compare its quality (mainly tablet dissolution) with what
is available in the local and internationalmarket using a home
developedmethod.Themethodwill be validated according to
the international standards [18, 19]. The developed analytical
method will be applied in quantification of rutin in both
raw material and its final tablet dosage form. The dissolution
of our developed tablet formulation will be evaluated and
will be compared to the dissolution of other rutin tablets
that are available in the market. Moreover, a stability study
under normal and stress conditions will be conducted for
our formulated tablet [20]. Our validated methods can be
included in one of the international pharmacopeia.Moreover,
the quality R&D and quality control lab sections of the herbal
industry can benefit from this research project to improve
their herbal products and control its quality.
2. Materials and Methods
2.1. Materials. All reagents used in this study had the min-
imum requirements set by American Society for Testing
Material (ASTM) and American Chemical Society (ACS)
specifications for analytical reagents. All the chemicals used
were purchased from reliable sources; these chemicals and
materials include the following: acetone, acetonitrile, ethanol,
and potassium dihydrogen phosphate were purchased from
Sigma Aldrich, St. Louis, USA. Hydrochloric acid 32%,
hydrogen peroxide 30%, isopropyl alcohol, methanol, and
tetrahydrofuranwere purchased fromThermo Fisher GmbH,
Karlsruhe, Germany.
Rutin trihydrate powder 99% was purchased from Sigma
Aldrich, St. Louis, USA. All tablet excipients were given
as a gift from the Jerusalem Pharmaceutical Company, and
these excipients include aerosil, acdisol, magnesium stearate,
and microcrystalline cellulose (MCC). Rutin tablet (Solgar-
Leonia, New Jersey, USA) was purchased from a local com-
munity pharmacy shop and was used as a market reference.
2.2. Instrumentation. The instruments that were used during
our research include the following: disintegration testers
(Erweka, Model-ZT 220, Germany), UV/visible spectropho-
tometer (JENWAY, Model-7315, Staffordshire, UK), Paddle
Dissolution Tester (HSIANGTAI, Model-DT-6), pH meter
(JENWAY, Model-3510 Staffordshire, UK), hotplate stirrer
(LabTech Model-ES35A, Hopkinton, USA), analytical bal-
ance (Nevada Weighing, Model-220), and multicheck of
hardness, thickness, and diameter (Erweka, Model-5.1, Ger-
many), oven (BINDER,Model-ED56, Germany), and rotava-
por (Heidolph, Model-VV2000, Schwabach, Germany).
2.3. Analytical Method Development
2.3.1. Determination of Wavelength of Maximum Absorption
(𝜆max) of Rutin. Rutin (0.1mg/ml) was dissolved in solvent
diluent (methanol : water; 9 : 1) and the UV-Vis spectrum of
rutin trihydrate was tested using UV spectrophotometer in
the range of 200–800 nm. The interfering effect of excipients
on the maximum absorption (𝜆max) was tested by scanning
the spectrumof each excipient alone aswell as in combination
with rutin.
2.3.2. Determination of Rutin Hydrochloride in Bulk. The
developedmethodwas applied to determine rutin in bulk. An
accurate weight (10mg) of rutin bulkmaterial was transferred
into a 100ml volumetric flask containing 20ml of diluent and
the volume was made up to the mark using the same diluent.
Appropriate volume 40ml of this solution was transferred
to a 100ml volumetric flask, and the volume was adjusted
to the mark using diluent. The absorption was recorded at
360 nm and the concentrations of the drug were calculated
from linear regression equations.The % recovery and % RSD
of the rutin in bulk were calculated for 5 repeated tests.
2.3.3. Analysis of Formulated and Commercial Tablet Formu-
lation. The developed method was also applied to determine
rutin in tablets. An average weight of rutin tablet was taken in
a 250ml volumetric flask and the volume was made up to the
mark with diluent. From this, 4ml was taken and transferred
to a 100ml volumetric flask and the volume was made up to
the mark with diluent to give 0.04mg/ml concentration. The
absorption was recorded at 360 nm and the concentrations of
the drug were calculated from the linear regression equation.
The% assay and % RSD of the rutin in tablets were calculated
for 5 repeated tests.
2.4. Analytical Method Validation. The linearity and range
of the developed method were performed by measuring
the absorption of a series of rutin standard solutions
(0.009–0.09mg/ml) at 𝜆max of 360 nm. The absorptions of
these standard solutions were plotted against their concen-
tration. The regression line equation and the square of the
correlation coefficient (𝑅2) were calculated.
The accuracy and precision validation parameters were
evaluated by testing three concentrations (80%, 100%, and
120%) of the rutin theoretical value, and three replicates of
each concentration were tested.
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Table 1: Compositions of formulated tablets.
Component Formula (F1) Formula (F2) Formula (F3)
Rutin 250 250 250
MCC 182 180 185
Magnesium stearate 5 5 5
Aerosil 5 5 5
Acdisol 8 10 5
Total weight 450 450 450
The recovery and precision were performed by test-
ing three prepared working solutions that are equivalent
to 80, 100, and 125% of the test concentration. Triplicate
measurements were done for each prepared solution. The
measurements were repeated for three consecutive days. The
percentage recovery and % RSD were then calculated.
The selectivity of the method was carried out by mea-
suring the absorbance of the excipients mixture without the
active ingredient. The absorbance was measured in the range
of 200–800 nm.The resulting spectrum of the excipients was
compared to that of rutin and was checked for any interfer-
ence at measuring 𝜆max of 360 nm. The method specificity
and selectivity were also checked for any interference of
degradative substances. This was performed by subjecting
the sample solution to forced degradation conditions. Forced
degradation was carried out by exposing the formulation
solution (0.04mg/ml) to four stress conditions, 0.1 N HCl,
0.1 N NaOH, 0.3% H
2
O
2
, and UV light at 254 nm for 3 hrs.
Moreover, the rutin formulated tablets were subjected to high
temperature (40∘C) for 150 days.
The robustness of the method was performed by examin-
ing the effect of slight changes on absorption at wavelengths
360 ± 2, the effect of slight changes in diluents composition in
the ratio of methanol : water; 9 : 2, andmethanol : water; 10 : 1,
was also examined.The effect of changing personnel has been
studied by using another analyst.
The LOD and LOQ of the method were calculated based
on the standard deviation of the response (𝜎) and slope
approach as defined in ICH guidelines [21]. LOD and LOQ
were calculated according to 3.3 ∗ 𝜎/Slope for LOD and10 ∗ 𝜎/Slope for LOQ.
2.5. Tablet Formulation Development. Three different formu-
lae of Rutin 250mg tablets were prepared in our research
lab. The components used are rutin trihydrate, magne-
sium stearate, microcrystalline cellulose (MCC), aerosil, and
acdisol.The detailed composition of the three tablet formula-
tions are listed in Table 1.The tablets were prepared by “direct
compression” method [9], according to the flowchart shown
in Figure 2.
2.6. Dissolution Profile of Formulated Rutin Tablet. Dissolu-
tion was done according to USP and ICH guidelines [22, 23].
The dissolution was done using USP apparatus 2 (paddle).
The dissolution test was performed in three different pH
media of 1.2 (0.1 N HCl), 4.5, and 6.8 phosphate buffer
prepared according to USP. The dissolution apparatus was
Weighing
Sifting
Mixing:
(1)
(2) Glidant
(3) Lubricant
Compression
API + filler/binder + disintegrant
Figure 2: Steps of formulation preparation.
run at 50 rpm and 37∘C for 45 minutes. One tablet was placed
into each of the six dissolution vessels containing 900ml of
dissolution medium. 10ml of the sample was withdrawn by
syringes from each dissolution vessel at time intervals of 5, 10,
15, 20, 25, 30, 35, 40, and 45 minutes. The average reading of
triplicatemeasurements was taken to calculate the percentage
of dissolved rutin using the following formula:
% of dissolved Rutin
= Actual amount of released rutin
Theoretical amount of rutin in tablet
∗ 100. (1)
The dissolution profiles of the formulated tablets and the
marketed rutin tablet were studied in the selected dissolution
media. Comparison of dissolution was based on the values of
the calculated similarity factor (𝑓
2
) and dissimilarity factor
(𝑓
1
) of the dissolution profile for the formulated and mar-
keted rutin tablets. Values for𝑓
1
and𝑓
2
were calculated using
(2) and (3), respectively.The 𝑓
2
factor measures the closeness
between two profiles and𝑓
1
measures difference between two
profiles. 𝑅
𝑡
and 𝑇
𝑡
in equations represent the percentages of
drug dissolved at each time point for the reference (market
tablet) and test (formulated tablet), respectively. An 𝑓
1
value
greater than 15 indicates significant dissimilarity, and an 𝑓
2
value greater than 50 indicates significant similarity [24–26]:
𝑓
1
= {[∑𝑛𝑡=1 󵄨󵄨󵄨󵄨𝑅𝑡 − 𝑇𝑡󵄨󵄨󵄨󵄨][∑𝑛
𝑡=1
𝑅
𝑡
] } × 100, (2)
𝑓
2
= 50 ⋅ log{[1 + 1𝑛
𝑛∑
𝑡=1
(𝑅
𝑡
− 𝑇
𝑡
)2]−0.5 × 100} . (3)
2.7. Weight Variation and Content Uniformity of the Formu-
lated Tablets. Weight variation of the formulated tablets was
performed in accordance with the USP method specified for
uncoated tablets [19].
The weight variation is done by weighing 20 tablets
individually and the test will be considered successful if it
meets the requirements set by the official pharmacopeia.
The content uniformity test was done in accordance with
USP. The rutin content for each tablet was calculated relative
to the label claim.
4 International Scholarly Research Notices
Table 2: Recovery and intraday precision assay of home prepared formula of rutin 250mg tablet.
Day
Rutin (mg/ml)
% RSD ANOVA % recoverySample number
1 2 3
80%
1 0.0317 0.0317 0.0313 0.026
0.63
98.55 ± 0.7
2 0.0317 0.0313 0.0317 0.026 98.55 ± 0.7
3 0.0317 0.0320 0.0320 0.026 99.73 ± 0.7
100%
1 0.0415 0.0415 0.0415 0.000
0.11
103.65 ± 0
2 0.0411 0.0407 0.0407 0.020 102.08 ± 0.5
3 0.0415 0.0411 0.0415 0.020 103.34 ± 0.5
125%
1 0.0509 0.0509 0.0505 0.016
0.178
101.52 ± 0.4
2 0.0513 0.0513 0.0509 0.016 102.27 ± 0.4
3 0.0509 0.0513 0.0509 0.016 102.02 ± 0.4
2.8. The Physical Specification. The disintegration time of
our formulated tablet was performed according to USP [27].
When all the tablets have been completely disintegrated, this
was recorded as disintegration time.
Tablet physical specifications like the hardness, thickness,
and diameter were determined and tested using multicheck
(Erweka 5.1). The test was done on ten tablets; the average
reading was assigned as the tablet hardness, thickness, and
diameter specifications of the formulated tablets.
2.9. Stability of Formulated Rutin Tablet. The stability of the
formulated rutin tablet was studied by storing the tablet at
room temperature as well as at 40∘C and analyzed period-
ically by using the developed analytical test method. The
percentage content of formulated rutin tablets was calculated
periodically through 150 days.
3. Results
3.1. Analytical Method Development. The spectrum of rutin
solution in the range of 200–800 nm showed two absorption
maxima, at 360 nm and at 260 nm. The results also demon-
strated no interference of the excipient used in formulation
at the measuring absorption maxima (Figure 3).
The developed method was applied to determine rutin in
bulk and tablets. The % amount of bulk rutin recovered was
between 98.92% and 100.33% and the % RDS was 1.22. The %
assay of rutin tablets was between 98.24% and 101.31% and the
RSD was 1.32.
3.2. Analytical Method Validation Results. The absorption of
serial standard solutions in the range of 0.009–0.09mg/ml
was plotted against its concentration and the regression line
was examined for linearity over the concentration range. The
curve was linear with a regression line equation of 𝑦 =25.035𝑥 + 0.0634. The goodness-of-fit (𝑅2) was also found
to be 0.999 indicating a linear relationship in the mentioned
range.
10
9
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0
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Exepient
Figure 3: Spectrum of rutin and excipients in the range of
200–800 nm.
The accuracy and precision of the method were estab-
lished on the results of three concentration levels around
concentration test value of rutin (80%, 100%, and 120%). The
results of the recovery of rutin active ingredient showed a
good accuracy (98.55–103.34).
The prepared solutions were tested for precision in three
replicates and an intraday testing for three consecutive days
(intermediate precision).The results indicate that themethod
is precise; the % RSD for the intraday was in the acceptable
range (0.016–0.026) and 𝑃 value of the ANOVA results
(intermediate precision) was >0.05 (Table 2).
The results stability-indicating study of formulated rutin
tablet under stress conditions of 0.1 N NaOH, 0.1 N HCl, UV
light (254 nm), and 0.3% H
2
O
2
showed that rutin tablets are
only stable in the UV light and slightly degraded in the H
2
O
2
as the percentage assay has dropped from 104% to about
80%. The results also demonstrate that instant degradation
has occurred on the tablet after the addition of alkaline and
acidic solution, and the assay dropped to about 60%.
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Figure 4:Dissolution profile of three formulations in the dissolution
media (pH 6.8).
3.3. Weight Variation and Content Uniformity of Rutin Tablet.
Weight variationwas performed according toUSP; the results
show that the variation for any of tested tablets was not more
than 2.6% from the mean weight.
Theuniformity content test was also performed according
to the USP; the results show that % RSD value of the assayed
tablets was 1.05 and no tablet % assay was out of the limit
(85–115%).
3.4. Dissolution Profile. The dissolution profile was done to
compare in vitro dissolution profiles of different rutin tablet
formulation. The results clearly demonstrate that formula 1
(F1) has the best dissolution among three formulations.Thus,
we selected formula 1 (F1) for the shelf life, accelerated, and
stress stability studies (Figure 4).
The results also show amoderate dissolution (26.7%) after
45 minutes, but it reaches a plateau after approximately 20
minutes. The low dissolution of the tablet was due to the low
solubility of rutin in aqueous media.
In order to test the dissolution profile of the other dissolu-
tionmedia, F1 was tested in three different dissolutionmedia,
namely, phosphate buffer 6.8, phosphate buffer 4.5, and 0.1 N
HCl; the dissolution was not significantly different between
the three media (𝑃 < 0.05). Furthermore, the dissolution
for the formulated rutin tablet (F1) and for marketed rutin
tablet was tested using phosphate buffer of pH 6.8.The results
(Figure 5) show slightly higher dissolution for our formulated
tablet compared to the rutin tablet.
3.5. The Physical Specification. Some of the physical parame-
ters of our formulated tablet including disintegration, hard-
ness, thickness, and diameter were determined as tablet
specification.
The disintegration of the tablet was performed using USP
specified disintegration apparatus. The tablets were placed in
the specified baskets and observed for complete disintegra-
tion. The formulated tablets were seen to disintegrate totally
after 4 minutes.
The tablets were tested for their hardness, thickness, and
diameter simultaneously using Erweka multicheck instru-
ment. The average value of the tested parameters will be
0
5
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30
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Comercial tablet
Fromulated tablet
−5
Figure 5: Dissolution profile for formulated rutin and commercial
rutin tablet at phosphate buffer media (pH = 6.8).
Table 3: Hardness, diameter, and thickness of the formulated tablet.
Tablet specification Average Minimum Maximum
Weight (mg) 445.4 440.7 450.9
Thickness (mm) 2.31 2.29 2.35
Hardness (N) 253 227 284
Diameter (mm) 13.03 12.99 13.09
Table 4: Stability of tablets at room temperature and 40∘C.
Day Tablet stored 40
∘C
(% assay )
Tablet stored at room
temperature (% assay)
7 96.38 106.41
14 95.98 103.58
150 91.69 96.33
considered as our tablet specification. Table 3 shows the
detailed data of the tested parameters.
3.6. Stability of Formulated Rutin Tablet. To study the tablet’s
stability, the formulated tablets were stored in room tempera-
ture at 40∘C andwere analyzed periodically through 150 days.
The results indicate the tablets and the tablet assay after 150
days at room temperature and 40∘C were 96.33 and 91.69,
respectively (Table 4).
4. Discussions
The spectrum shows two absorption maxima, at 360 nm and
at 260 nm. The absorption at 260 nm was linear with an𝑅2 almost similar to 360 nm. However, we adapted 360 nm
as a measuring wavelength in our analytical method to
avoid any absorption from the excipient and degradation
product. To examine absorptivity of the excipients on the
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measuring 𝜆max 360 nm, all the expected excipients which
were included in formulation were dissolved in the diluents
and their absorbance wasmeasured.The results show that the
absorbance at the selected 𝜆max is negligible relative to rutin
absorption at 𝜆max 360 nm. The result clearly demonstrates
that there is no interaction between the excipients and rutin
active ingredient and thewavelength is selective for rutin.The
specificity and selectivity of the developed analytical method
were also tested by stability-indicating study. The formulated
rutin tablet was put under different stress conditions: 0.1 N
NaOH, 0.1 N HCl, UV light (254 nm), and 0.3% H
2
O
2
. The
results showed that method can selectively quantify any drop
in the assay of rutin in the formulated tablets under the above
selected stress conditions.
The results clearly demonstrate that our formulated
tablets comply with weight variation and the content unifor-
mity; according to USP, weight variation test will pass only
if not more than two of the individual weights deviate from
the average weight by ±7.5% and none deviates by more than
twice that percentage. Our results show that the variation for
any of the tested tablets was not more than 2.6% from the
mean weight. The uniformity content according to the USP
will pass if the relative standard deviation (% RSD) is ≤15 and
no % assay value is outside 85–115%. The test fails if one or
more values are outside 75–125%.The uniformity content test
results showed that RSDvalue of the assayed tablets was 1.05%
and no tablet has % assay that was out of the limit (85–115%).
The rutin dissolution profile of the formulated tablet showed
a slight dissolution improvement over the marketed rutin
tablet. However, the result of similarity factor (f2) was >50
and the dissolution data revealed that there was no statistical
difference (𝑃 > 0.05) between the formulated tablet and the
marketed one.
The developed analytical method showed good linearity,
accuracy, precision, and specificity. This study recommends
a simple, validated analytical method for herbal and food
supplement manufacturers to use in quality control of their
products.
5. Conclusion
In this study, we developed a tablet formulation of rutin
250mg in our research labs, and we also developed a simple
validated UVmethod for analysis and quantification of rutin
in formulated tablets as well as raw material. The dissolution
profile of our formulated tablet was slightly more than the
marketed rutin tablet.The shelf and accelerated stability study
results of the formulated tablet showed that the formulated
tablets are stable. This study can guide companies that
manufacture herbal products to improve their formulated
herbals and apply validated analytical methods to check their
product quality.
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